InsiderSignal.AI

InsiderSignal.ai

ANNX - Annexon, Inc.

Insider Purchase by Choi Jung (Dir)

3 Months
After Trade
Before Trade

Loading data...

Trade Summary

2 months ago, Choi Jung, serving as Dir at Annexon, Inc. (ANNX), purchased 33,000 shares at $4.19 per share, for a total transaction value of $138,270.00. Following this transaction, Choi Jung now holds 33,000 shares of ANNX.

The trade was executed on Monday, December 1, 2025 and publicly disclosed via SEC Form 4 filing on Wednesday, December 3, 2025, 2 days after the trade was made.

Annexon, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Choi Jung

Dir

Jung E. Choi is an accomplished biotechnology executive serving as an independent Director on the Board of Directors of Annexon, Inc. (NASDAQ: ANNX), a clinical-stage biopharmaceutical company developing therapies for complement-mediated diseases.[[2]](https://www.bio.org/events/bio-investor-forum/speakers/1233967)[[3]](https://annexonbio.com/about/)[[4]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-annx/annexon/news/independent-director-of-annexon-jung-choi-buys-more-stock) On December 1, 2025, she purchased 33,000 shares at $4.19 per share, signaling confidence in the company's prospects amid market volatility.[[1]](https://www.ainvest.com/news/annexon-directors-carson-choi-buy-shares-market-volatility-2512/)[[4]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-annx/annexon/news/independent-director-of-annexon-jung-choi-buys-more-stock)[[5]](https://www.tipranks.com/news/insider-trading/director-makes-bold-move-with-major-stock-purchase-in-annexon-biosciences-insider-trading) Choi has a distinguished career in biotech business development, having led over 50 transactions exceeding $13 billion in value. She joined Global Blood Therapeutics (GBT) in 2015 as Chief Business and Strategy Officer, overseeing business development, corporate strategy, patient advocacy, and government affairs. Previously, she was Senior Vice President of Corporate Development at InterMune (acquired by Roche) and Chimerix, and held leadership roles at Gilead Sciences, including building the corporate development group and launching Hepsera for chronic hepatitis B. Earlier positions include Vice President at Bay City Capital and Engagement Manager at McKinsey & Company. She holds a B.A. in human biology and an M.B.A. from Stanford University, and is an Aspen Health Innovators Fellow.[[2]](https://www.bio.org/events/bio-investor-forum/speakers/1233967)

View full insider profile →

Trade Price

$4.19

Quantity

33,000

Total Value

$138,270.00

Shares Owned

33,000

Trade Date

Monday, December 1, 2025

83 days ago

SEC Filing Date

Wednesday, December 3, 2025

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Annexon, Inc.

Company Overview

No company information available
View news mentioning ANNX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/1920090

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime